Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia

dc.contributor.authorGormez, Selcuk
dc.contributor.authorKirisoglu, Ceyda Erel
dc.contributor.authorEkicibasi, Mehmet Erkan
dc.contributor.authorDegirmencioglu, Aleks
dc.contributor.authorPaudel, Ashok
dc.contributor.authorAkan, Gokce
dc.contributor.authorAtalar, Fatmahan
dc.contributor.authorSariguzel, Nevin
dc.contributor.authorPamukcu, Burak
dc.date.accessioned2023-02-21T12:38:13Z
dc.date.available2023-02-21T12:38:13Z
dc.date.issued2021-01-01
dc.description.abstractObjective: To compare the prevalence of hypertension and pre-existing use of renin-angiotensin-aldosterone system blockers in patients with coronavirus disease (COVID-19) and non-COVID-19 viral pneumonias. Methods: Real-time polymerase chain reaction confirmed COVID-19 and non-COVID-19 pneumonia patients were retrospectively analyzed. The presence of hypertension, coronary artery disease (CAD), and pre-existing use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) were compared between the groups. Results: A total of 103 COVID-19 and 91 non-COVID-19 hospitalized viral pneumonia patients were enrolled. Hypertension and CAD were more common in patients with non-COVID-19 viral pneumonia than in patients with COVID-19 (39.6\% vs 22.3\%, respectively, p=0.012 and 24.2\% vs 4.9\%, respectively, p<0.001). In our study, 2.9\% and 6.8\% of patients with COVID-19 were on ACEIs and ARBs, respectively, whereas 13.2\% and 19.8\% of patients with non-COVID-19 viral pneumonia were on ACEIs and ARBs, respectively (p=0.009 and p=0.013). Neutrophil-to-lymphocyte ratio (p<0.001) was prominent in patients with non-COVID-19 viral pneumonia compared with patients with COVID-19. Conclusion: Our study results indicate that hypertension and CAD are more common among patients with non-COVID-19 viral pneumonia than patients with COVID-19. The prevalence of ACEIs and ARBs use was not higher in patients with COVID-19. Our results support that the use of ACEIs and ARBs do not play a specific role in patients with COVID-19.
dc.description.issue4
dc.description.issueJUN
dc.description.pages286+
dc.description.volume49
dc.identifier.doi10.5543/tkda.2021.87750
dc.identifier.urihttps://hdl.handle.net/11443/2354
dc.identifier.urihttp://dx.doi.org/10.5543/tkda.2021.87750
dc.identifier.wosWOS:000658329900007
dc.publisherAVES
dc.relation.ispartofTURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY
dc.subjectCOVID-19
dc.subjectviral pneumonia
dc.subjecthypertension
dc.subjectangiotensin-converting enzyme inhibitors
dc.subjectangiotensin II type 2 receptor blockers
dc.titleComparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
TKDA-87750-ORIGINAL_ARTICLE-PAMUKCU.pdf
Size:
1.37 MB
Format:
Adobe Portable Document Format

Collections